Boxer Capital

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics to target high-value, validated oncogenic drivers. It employs structure-guided drug discovery and advanced computational chemistry to create small-molecule therapies that selectively address oncogenic alterations, with the aim of improving patient outcomes in cancer.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics to target high-value, validated oncogenic drivers. It employs structure-guided drug discovery and advanced computational chemistry to create small-molecule therapies that selectively address oncogenic alterations, with the aim of improving patient outcomes in cancer.

Incyclix Bio is a biotechnology company based in Durham, North Carolina, focused on developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. Founded in 2020 by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman, the company aims to provide potent and selective inhibition of challenging CDK targets. Incyclix Bio's innovative approach seeks to equip pharmaceutical companies and medical practitioners with novel therapeutic options, enhancing the treatment landscape for cancer patients.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics to target high-value, validated oncogenic drivers. It employs structure-guided drug discovery and advanced computational chemistry to create small-molecule therapies that selectively address oncogenic alterations, with the aim of improving patient outcomes in cancer.

Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe allergies and inflammation. The company is focused on advancing its lead product candidate, THB001, which is a first-in-class, highly selective oral inhibitor of the KIT receptor, a key regulator of mast cell function and survival. Mast cells play a crucial role in mediating inflammation in allergic diseases, making this targeted approach significant for treatment. Additionally, Third Harmonic Bio is developing THB335, another potent and selective oral small-molecule KIT inhibitor aimed at addressing various mast cell-driven inflammatory conditions affecting the skin, airway, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to provide new options for patients suffering from inflammatory diseases.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Flare Therapeutics is a biotechnology company that develops small-molecule medicines by targeting transcription factors. It focuses on identifying switch sites—druggable regions that regulate transcription factor activity—to address disease-causing mutations. Leveraging insights into transcription factor biology, Flare aims to translate this understanding into precision medicines, building an early pipeline that is initially focused on precision oncology with potential expansions into neurology, rare genetic disorders, immunology, and inflammation. The company combines a drug-discovery platform with a biology-led approach to discover therapies that alter the trajectory of diseases driven by transcription factor dysregulation.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline's proprietary technology platform leverages advanced methods in induced pluripotent stem cell (iPSC) differentiation and genetic programming, specifically targeting the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, improving their anti-cancer activity. Shoreline's focus includes creating clinically effective immunotherapies using iPSC-derived NK cells and macrophages, providing innovative and cost-effective treatment options for oncology and other serious health conditions.

Biomea Fusion is a precision medicine company focused on accelerating cancer drug development by targeting specific gene alterations that drive tumor growth. Its lead program aims to disrupt the protein-to-protein interaction between menin and the MLL complex for treating various tumors.

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Cedilla Therapeutics, Inc. is a biotechnology company focused on developing targeted small-molecule therapeutics for cancer and diseases linked to protein dysregulation. The company employs innovative strategies to destabilize oncoprotein targets, utilizing methods such as direct ligand-induced degradation, disruption of stabilizing protein-protein interactions, and the identification of upstream regulators that affect protein stability. Cedilla's comprehensive approach also includes large-scale proteomic analyses to map protein susceptibility, enhancing the potential for effective therapies. By concentrating on the transitions between stable and susceptible protein states, Cedilla aims to create novel treatments that broaden the applicability of small molecule therapeutics beyond oncology. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company was formerly known as Protein Stability Newco, Inc. before rebranding in 2018.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Nurix Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing oral small-molecule therapies that modulate cellular protein levels to treat cancer and immune disorders. It operates DELigase, an integrated discovery platform that targets E3 ligases to alter protein abundance within cells. The company's product pipeline includes targeted protein degraders such as NX-2127, an oral Bruton's tyrosine kinase degrader for relapsed or refractory B-cell malignancies, and NX-1607, an oral Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications; these are in preclinical stages. Nurix also explores inhibitors of CBL-B, an E3 ligase that regulates T cell activation. The company collaborates with major industry partners, including Gilead Sciences and Sanofi, and was founded in 2009 and is headquartered in San Francisco.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology, chimeric autoantibody receptor (CAAR) T cells, selectively targets and eliminates disease-causing B cells while sparing healthy ones. Cabaletta's lead product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris.

Akero Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, with a primary emphasis on nonalcoholic steatohepatitis (NASH). Its lead program is a long-acting fibroblast growth factor 21 (FGF21) analog designed to restore metabolic balance and address liver fat, inflammation, and fibrosis. The company was founded in 2017 and is headquartered in South San Francisco, California.

Atreca is a biopharmaceutical company that discovers and develops antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from its proprietary discovery platform.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.